USFDA grants approval for Aduhelm as the first and only Alzheimer’s drug in almost two decades

USFDA grants approval for Aduhelm as the first and only Alzheimer’s drug in almost two decades In clinical trials, Aduhelm reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatment. The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease. https://ift.tt/eA8V8J